Abstract Details

Title Effects of probiotic, prebiotic or synbiotic supplementation on Parkinson's Disease: A systematic review with meta-analysis

Topic Movement Disorders

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-003

Background

In recent years the “gut-brain axis” has shown to play an important role in Parkinson's disease. Evidence indicates that microbiota stimulation influences positively on CNS diseases mediating different pathways, such as neural, hormonal, immune, and antioxidant signaling. Therefore, we performed a systematic review with meta-analysis to evaluate the efficacy and security of those supplementation in Parkinson disease.

Objective

To evaluate the efficacy and safety of probiotic, prebiotic, or synbiotic supplementation on clinical profiles in patients with Parkinson's disease.

Design/Methods A systematic search was performed in PubMed, Ovid-Medline, Embase, Scopus, Cochrane Library, Web of Science, and Google Scholar until July 2021. We included observational studies and clinical trials. The quality of studies was evaluated according to study designs. Data were extracted to perform a meta-analysis using random-effects models with the DerSimonian-Laird method. Heterogeneity was evaluated using the Cochran Q and I² statistics. The metacont function in R 4.1.0 was used.

Results We screened 62 studies for full-text review from 1542 in the initial search. We selected 9 studies for qualitative synthesis. Five randomized controlled trials were analyzed quantitatively with a total of 357 Parkinson's disease patients. Meta-analysis showed that compared with placebo, there was an increase in BMI (SMD: 0.50; 95%IC: 0.19; 0.82), bowel movements per week (SMD: 0.95; 95%IC: 0.42; 1.48) and Bristol stool scale (SMD: 0.62; 95%IC: 0.32; 0.92). Similarly, there was a decrease in the frequency of use of laxatives (SMD: -0.55; 95%IC: -0.85; -0.25). No significant adverse effects were reported, only dizziness, bloating and lethargy.

Conclusions This review showed that probiotics, prebiotic, or synbiotics could be effective in some symptoms among Parkinson's Disease patients.

Authors/Disclosures
Nicanor Mori, MD (Hospital Daniel Alcides Carrion) PRESENTER	Dr. Mori has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Mori has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi.
Miguel F. Cabanillas Lazo	Mr. Cabanillas Lazo has nothing to disclose.
Milagros D. Pascual-Guevara (Universidad Nacional Mayor de San Marcos)	Miss Pascual-Guevara has nothing to disclose.
	No disclosure on file
	No disclosure on file
Carlos Alva-Diaz	No disclosure on file